High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Singh, D.; Vignat, J.; Lorenzoni, V.; Eslahi, M.; Ginsburg, O.; Lauby-Secretan, B.; Arbyn, M.; Basu, P.; Bray, F.; Vaccarella, S. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health 2023, 11, e197–e206. [Google Scholar] [CrossRef]
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- de Sanjose, S.; Quint, W.G.; Alemany, L.; Geraets, D.T.; Klaustermeier, J.E.; Lloveras, B.; Tous, S.; Felix, A.; Bravo, L.E.; Shin, H.-R.; et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11, 1048–1056. [Google Scholar] [CrossRef]
- Mariani, L.; Monfulleda, N.; Alemany, L.; Vizza, E.; Marandino, F.; Vocaturo, A.; Benevolo, M.; Quirós, B.; Lloveras, B.; Klaustermeier, J.E.; et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer 2010, 10, 259. [Google Scholar] [CrossRef] [PubMed]
- Humans IWG on the E of CR to. Human Papillomavirus (HPV) Infection; International Agency for Research on Cancer: Lyon, France, 2007. Available online: https://www.ncbi.nlm.nih.gov/books/NBK321770/ (accessed on 27 February 2022).
- Guan, P.; Howell-Jones, R.; Li, N.; Bruni, L.; de Sanjosé, S.; Franceschi, S.; Clifford, G.M. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131, 2349–2359. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Franceschi, S.; Howell-Jones, R.; Snijders, P.J.F.; Clifford, G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 2011, 128, 927–935. [Google Scholar] [CrossRef] [PubMed]
- Jacobson, G.; Chuang, L.; Pankow, M. Improving quality of care and timely access to radiation therapy for patients with invasive cervical cancer at the National Cancer Institute Paraguay. Gynecol. Oncol. Rep. 2018, 25, 82–86. [Google Scholar] [CrossRef] [PubMed]
- Allanson, E.R.; Zafar, S.N.; Anakwenze, C.P.; Schmeler, K.M.; Trimble, E.L.; Grover, S. The global burden of cervical cancer requiring surgery: Database estimates. Infect. Agent. Cancer 2024, 19, 5. [Google Scholar] [CrossRef]
- Davies-Oliveira, J.C.; Smith, M.A.; Grover, S.; Canfell, K.; Crosbie, E.J. Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. Clin. Oncol. (R. Coll. Radiol.) 2021, 33, 550–559. [Google Scholar] [CrossRef]
- Simms, K.T.; Steinberg, J.; Caruana, M.; Smith, M.A.; Lew, J.-B.; Soerjomataram, I.; Castle, P.E.; Bray, F.; Canfell, K. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–2099: A modelling study. Lancet Oncol. 2019, 20, 394–407. [Google Scholar] [CrossRef]
- Murillo, R.; Almonte, M.; Pereira, A.; Ferrer, E.; Gamboa, O.A.; Jerónimo, J.; Lazcano-Ponce, E. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008, 26 (Suppl. 11), L37–L48. [Google Scholar] [CrossRef]
- Herrero, R.; Ferreccio, C.; Salmerón, J.; Almonte, M.; Sánchez, G.I.; Lazcano-Ponce, E.; Jerónimo, J. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine 2008, 26 (Suppl. 11), L49–L58. [Google Scholar] [CrossRef]
- Adedimeji, A.; Ajeh, R.; Pierz, A.; Nkeng, R.; Ndenkeh, J.J.; Fuhngwa, N.; Nsame, D.; Nji, M.; Dzudie, A.; Anastos, K.M.; et al. Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context. BMC Womens Health 2021, 21, 74. [Google Scholar] [CrossRef]
- Kane, M.A.; Serrano, B.; de Sanjosé, S.; Wittet, S. Implementation of human papillomavirus immunization in the developing world. Vaccine 2012, 30 (Suppl. 5), F192–F200. [Google Scholar] [CrossRef]
- Burger, E.A.; Portnoy, A.; Campos, N.G.; Sy, S.; Regan, C.; Kim, J.J. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. Int. J. Cancer 2021, 148, 932–940. [Google Scholar] [CrossRef] [PubMed]
- Goldie, S.J.; O’Shea, M.; Campos, N.G.; Diaz, M.; Sweet, S.; Kim, S.-Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26, 4080–4093. [Google Scholar] [CrossRef]
- Correa, R.M.; Baena, A.; Valls, J.; Colucci, M.C.; Mendoza, L.; Rol, M.; Wiesner, C.; Ferrera, A.; Fellner, M.D.; González, J.V.; et al. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS ONE 2022, 17, e0272205. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.-Q.; Hao, J.-Q.; Mendez, M.J.G.; Mohamed, S.B.; Fu, S.-L.; Zhao, F.-H.; Qiao, Y.-L. The Prevalence of Cervical HPV Infection and Genotype Distribution in 856,535 Chinese Women with Normal and Abnormal Cervical Lesions: A Systemic Review. J. Cytol. 2022, 39, 137–147. [Google Scholar] [CrossRef] [PubMed]
- Baloch, Z.; Yuan, T.; Wang, B.; Tai, W.; Feng, Y.; Liu, Y.; Li, X.; Feng, Y.; Liu, L.; Zhang, A.M.; et al. Ethnic and geographic variations in HPV prevalence and genotype distribution in north-western Yunnan, China. J. Med. Virol. 2016, 88, 532–540. [Google Scholar] [CrossRef]
- Raçi, P.Z.; Raçi, F.; Hadri, T. Kosovo women’s knowledge and awareness of human papillomavirus (HPV) infection, HPV vaccination, and its relation to cervical cancer. BMC Womens Health 2021, 21, 354. [Google Scholar] [CrossRef]
- Zejnullahu Raçi, P.; Hošnjak, L.; Poljak, M.; Lepej, S.Ž.; Vince, A. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics. Ginekol. Pol. 2018, 89, 485–494. [Google Scholar] [CrossRef] [PubMed]
- Tambouret, R.H. The evolution of the Papanicolaou smear. Clin. Obstet. Gynecol. 2013, 56, 3–9. [Google Scholar] [CrossRef] [PubMed]
- Rijkaart, D.C.; Berkhof, J.; Van Kemenade, F.J.; Coupe, V.M.; Rozendaal, L.; Heideman, D.A.; Verheijen, R.H.; Bulk, S.; Verweij, W.; Snijders, P.J.; et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): Results and implications. Br. J. Cancer 2012, 106, 975–981. [Google Scholar] [CrossRef] [PubMed]
- Ogilvie, G.S.; Krajden, M.; van Niekerk, D.J.; Martin, R.E.; Ehlen, T.G.; Ceballos, K.; Smith, L.W.; Kan, L.; Cook, D.A.; Peacock, S.; et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: Results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Br. J. Cancer 2012, 107, 1917–1924. [Google Scholar] [CrossRef] [PubMed]
- Gilham, C.; Sargent, A.; Kitchener, H.C.; Peto, J. HPV testing compared with routine cytology in cervical screening: Long-term follow-up of ARTISTIC RCT. Health Technol. Assess. (Winch. Engl.) 2019, 23, 1–44. [Google Scholar] [CrossRef]
- Perkins, R.B.; Guido, R.S.; Castle, P.E.; Chelmow, D.; Einstein, M.H.; Garcia, F.; Huh, W.K.; Kim, J.J.; Moscicki, A.-B.; Nayar, R.; et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J. Low. Genit. Tract Dis. 2020, 24, 102–131. [Google Scholar] [CrossRef] [PubMed]
- Pinto, L.A.; Dillner, J.; Beddows, S.; Unger, E.R. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 2018, 36, 4792–4799. [Google Scholar] [CrossRef] [PubMed]
- Gallagher, K.E.; Howard, N.; Kabakama, S.; Mounier-Jack, S.; Burchett, H.E.D.; LaMontagne, D.S.; Watson-Jones, D. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016. Papillomavirus Res. 2017, 4, 72–78. [Google Scholar] [CrossRef]
- Sah, A.K.; Joshi, B.; Khadka, D.K.; Gupta, B.P.; Adhikari, A.; Singh, S.K.; Rai, G.; Vaidya, G.S.; Rajbhandari, R.; Pant, B.; et al. Comparative Study of GeneXpert MTB/RIF Assay and Multiplex PCR Assay for Direct Detection of Mycobacterium tuberculosis in Suspected Pulmonary Tuberculosis Patients. Curr. Microbiol. 2017, 74, 1026–1032. [Google Scholar] [CrossRef] [PubMed]
- Cassani, B.; Soldano, G.; Finocchiaro, D.; Conti, S.; Bulfamante, A.; Lemorini, G.; Bulfamante, G. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples. Pathologica 2018, 110, 294–301. [Google Scholar]
- Poljak, M.; Seme, K.; Maver, P.J.; Kocjan, B.J.; Cuschieri, K.S.; Rogovskaya, S.I.; Arbyn, M.; Syrjänen, S. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2013, 31 (Suppl. 7), H59–H70. [Google Scholar] [CrossRef]
- Jansen, E.E.L.; Ivanuš, U.; Jerman, T.; de Koning, H.J.; de Kok, I.M.C.M. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia. Gynecol. Oncol. 2021, 160, 118–127. [Google Scholar] [CrossRef]
- EUROCHIP Working Group. Past, present and future of the cervical cancer screening in Latvia. Tumori J. 2010, 96, 529–537. [Google Scholar] [CrossRef] [PubMed]
- Anttila, A.; Ronco, G.; Clifford, G.; Bray, F.; Hakama, M.; Arbyn, M.; Weiderpass, E. Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 2004, 91, 935–941. [Google Scholar] [CrossRef]
- Atkinson, A.E.; Mandujano, C.A.M.; Bejarano, S.; Kennedy, L.S.; Tsongalis, G.J. Screening for Human Papillomavirus in a Low- and Middle-Income Country. J. Glob. Oncol. 2019, 5, JGO1800233. [Google Scholar] [CrossRef]
- Patterns and Trends in Human Papillomavirus-Related Diseases in Central and Eastern Europe and Central Asia. Available online: https://pubmed.ncbi.nlm.nih.gov/24332296/ (accessed on 12 May 2024).
- Bielska-Lasota, M.; Rossi, S.; Krzyżak, M.; Haelens, A.; Domenic, A.; De Angelis, R.; Maciejczyk, A.; Rodríguez-Barranco, M.; Zadnik, V.; Minicozzi, P.; et al. Reasons for low cervical cancer survival in new accession European Union countries: A EUROCARE-5 study. Arch. Gynecol. Obstet. 2020, 301, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Tachezy, R.; Smahelova, J.; Salakova, M.; Arbyn, M.; Rob, L.; Skapa, P.; Jirasek, T.; Hamsikova, E. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS ONE 2011, 6, e21913. [Google Scholar] [CrossRef] [PubMed]
- Davies, P.; Aluloski, I.; Aluloski, D.; Dizdarevic Maksumic, A.; Ghayrat Umarzoda, S.; Gutu, V.; Ilmammedova, M.; Janashia, A.; Kocinaj-Berisha, M.; Matylevich, O.; et al. Update on HPV Vaccination Policies and Practices in 17 Eastern European and Central Asian Countries and Territories. Asian Pac. J. Cancer Prev. 2023, 24, 4227–4235. [Google Scholar] [CrossRef]
- Bowden, S.J.; Ellis, L.B.; Kyrgiou, M.; Fiander, A.N.; Hibbitts, S. High Prevalence of HPV 51 in an Unvaccinated Population and Implications for HPV Vaccines. Vaccines 2022, 10, 1754. [Google Scholar] [CrossRef]
- Tjalma, W.A.; Depuydt, C.E. Cervical cancer screening: Which HPV test should be used–L1 or E6/E7? Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 170, 45–46. [Google Scholar] [CrossRef]
- Zhang, J.; Zhang, D.; Yang, Z.; Wang, X.; Wang, D. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: A study from a hospital in northeastern China. BMC Cancer 2020, 20, 443. [Google Scholar] [CrossRef] [PubMed]
- Kosovo* Introduces HPV Vaccine in Immunization Schedule: Outreach in Schools and Beyond to Reach Every Girl. Available online: https://www.who.int/europe/news/item/04-04-2024-kosovo--introduces-hpv-vaccine-in-immunization-schedule--outreach-in-schools-and-beyond-to-reach-every-girl (accessed on 14 May 2024).
- Empowering Women’s Health: Milestones and Collaborative Efforts in Cervical Cancer Prevention in Kosovo. Available online: https://kosovo.unfpa.org/en/news/empowering-womens-health-milestones-and-collaborative-efforts-cervical-cancer-prevention-kosovo (accessed on 28 June 2024).
Positive Genotypes | Count | % of Genotype Positive | % of Samples Genotyped | % of Total Samples |
---|---|---|---|---|
HPV 16 | 89 | 40.5% | 30.5% | 4.5% |
HPV 18 | 3 | 1.4% | 1.0% | 0.2% |
HPV 31 | 16 | 7.3% | 5.5% | 0.8% |
HPV 33 | 1 | 0.5% | 0.3% | 0.1% |
HPV 35 | 13 | 5.9% | 4.5% | 0.7% |
HPV 39 | 8 | 3.6% | 2.7% | 0.4% |
HPV 45 | 4 | 1.8% | 1.4% | 0.2% |
HPV 51 | 175 | 79.5% | 59.9% | 8.8% |
HPV 52 | 14 | 6.4% | 4.8% | 0.7% |
HPV 56 | 6 | 2.7% | 2.1% | 0.3% |
HPV 58 | 16 | 7.3% | 5.5% | 0.8% |
HPV 59 | 0 | 0.0% | 0.0% | 0.0% |
HPV 66 | 12 | 5.5% | 4.1% | 0.6% |
HPV 68 | 7 | 3.2% | 2.4% | 0.4% |
Coinfections | 120 | 54.5% | 41.1% | 6.0% |
Genotype | Count | % of Genotype Positive | % of Total Samples |
---|---|---|---|
HPV 16 | 142 | 82.1% | 71.0% |
HPV 18 | 17 | 9.8% | 8.5% |
HPV 31 | 8 | 4.6% | 4.0% |
HPV 33 | 3 | 1.7% | 1.5% |
HPV 35 | 2 | 1.2% | 1.0% |
HPV 39 | 0 | 0.0% | 0.0% |
HPV 45 | 15 | 8.7% | 7.5% |
HPV 51 | 0 | 0.0% | 0.0% |
HPV 52 | 1 | 0.6% | 0.5% |
HPV 56 | 0 | 0.0% | 0.0% |
HPV 58 | 4 | 2.3% | 2.0% |
HPV 59 | 2 | 1.2% | 1.0% |
HPV 66 | 1 | 0.6% | 0.5% |
HPV 68 | 2 | 1.2% | 1.0% |
Coinfections | 22 | 12.7% | 11.0% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bentz, J.L.; Barney, R.E.; Georgantzoglou, N.; Manxhuka-Kerliu, S.; Ibishi, V.A.; Dacaj-Elshani, B.; Bejarano, S.; Palumbo, P.E.; Suresh, A.; LaRochelle, E.P.M.; et al. High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases 2024, 12, 189. https://doi.org/10.3390/diseases12080189
Bentz JL, Barney RE, Georgantzoglou N, Manxhuka-Kerliu S, Ibishi VA, Dacaj-Elshani B, Bejarano S, Palumbo PE, Suresh A, LaRochelle EPM, et al. High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases. 2024; 12(8):189. https://doi.org/10.3390/diseases12080189
Chicago/Turabian StyleBentz, Jessica L., Rachael E. Barney, Natalia Georgantzoglou, Suzana Manxhuka-Kerliu, Vlora Ademi Ibishi, Brikene Dacaj-Elshani, Suyapa Bejarano, Paul E. Palumbo, Arvind Suresh, Ethan P. M. LaRochelle, and et al. 2024. "High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer" Diseases 12, no. 8: 189. https://doi.org/10.3390/diseases12080189
APA StyleBentz, J. L., Barney, R. E., Georgantzoglou, N., Manxhuka-Kerliu, S., Ibishi, V. A., Dacaj-Elshani, B., Bejarano, S., Palumbo, P. E., Suresh, A., LaRochelle, E. P. M., Keegan, W. P., Wilson, T. L., Dokus, B. J., Hershberger, K. C., Gallagher, T. L., Allen, S. F., Palisoul, S. M., Steinmetz, H. B., Kennedy, L. S., & Tsongalis, G. J. (2024). High-Risk HPV Screening Initiative in Kosovo—A Way to Optimize HPV Vaccination for Cervical Cancer. Diseases, 12(8), 189. https://doi.org/10.3390/diseases12080189